

9-23-04

Docket No: GI5358-CIP

Patent?

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re of Application of:

Kenneth JACOBS, et al

Application No.:

10/084,298

Group Art No.:

1647

Filed:

February 25, 2002

Examiner:

Rachel B. Kapust

For:

COMPOSITION AND METHOD FOR TREATING INFLAMMATORY

DISORDERS

Confirmation No.:

7985

Customer Number:

25291

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Preliminary Statements 1.

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV238505012US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

09/24/2004 SSESHE1 00000038 071060 10084298

01 FC:1806

180.00 DA

Docket No: GI5358-CIP

Patent

2.	Identification of Time of Filing							
		Inform	nation Disclosure Statement					
	a.	H	is filed within three months of the filing date of the application. is filed before the mailing date of a first Office Action on the merits.					
	b. c.		is filed before the mailing date of a first Office Action of the ments. is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
	d.	\boxtimes	is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p),					
	e.		as appropriate. is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).					
3.	\boxtimes		ification under 37 CFR 1.97(e) and 1.704(d) undersigned attorney certifies					
	a.		that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or					
	b.		Items 5 and 11-12 cited on the Information Disclosure Statement and PTO 1449 were cited in a communication from a foreign patent office in a counterpart foreign application, EP Application No. 00928535.4, no more than three months prior to the filing of the statement. A copy of the European Search Report issued in EP Application No. 00928535.4 mailed on July 14, 2004 is enclosed.					
	c.		certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.					
		Newly Cited Information A legible copy of Items 1-4 and 6-10 cited on the attached form PTO 1449 is enclosed. No copy of Items 5 and 11-12 cited on the attached form PTO 1449 is enclosed as these references have been cited to the Patent Office in the above referenced application on an Information Disclosure Statement filed on October 28, 2002. This statement includes the fee set forth in 37 CFR 1.17(p).						
		No c form to th	riously Cited Information copy of the patents, publications or other information cited on the attached PTO-1449 is enclosed because it has been previously cited by or submitted e Office in a prior application which is relied upon for an earlier filing date er 35 USC 120.					


Docket No: GI5358-CIP

Patent

Concise Explanation Documents cited above which are not in the English Language have been explained in the specification. have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.							
Form PTO-1449 is enclosed in duplicate.							
Fees Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00							
Method of Payment of Fees: Charge Deposit Account No. 07-1060 in the amount of \$180.00 A duplicate of this statement is enclosed.							
Instructions as to Overpayment/Underpayment: Credit any overpayment and charge any underpayment to Deposit Account No. 07-1060.							
Diane Colly							
Diana M. Collazo Attorney for Applicants							
Reg. No. 46,635							

Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. (617) 665-6073

S:\LACOMMON\PATENTS\AMEND\5358\CIP\Supp IDS 09-20-04.doc



Complete if Known				
Application Number	10/084,298			
Filing Date	February 25, 2002			
First Named Inventor	Kenneth JACOBS			
Group Art Unit	1647			
Examiner Name	Rachel B. Kapust			
Attorney Docket Number	GI5358-CIP			

				U.S. PATENT DOCU	MENTS	
		U.S. Patent Docu	ument		Date of Publication of	Pages, Columns, Lines,
Examiner Initials*	Cite No.	Number (If known)	Kind Code (If Known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	1.	2003/0170823		Presnell, S.R., et al	09-11-2003	
	2.	2004/0023341		Wenfeng, et al	06-10-2004	
	3.	2004/0152125		Presnell, S.R., et al	08-05-2004	
	4.	2004/0180399		Renauld, J.C., et al	09-16-2004	

			F	DREIGN F	PATENT DOCUMENTS			
Examiner	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
. Initials*	No.	Office	Number	Kind Code (If Known)	Applicant of Cited document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Т
	5.		WO 2000/24758		Ludwig Institute for Cancer Research		05-04-2000	

		OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	6.	Bork, P., Genome Research 10:398-400, 2000			
	7.	Doerks, et al, Trends in Genetics 14:248-250, 1998			
	8.	Smith, et al, Nature Biotechnology 15:1222-1223, 1997			
	9.	Brenner, S.E., Trends in Genetics 15:132-133, 1999			
	10.	Mahairas, et al., PNAS, USA, 96(17) 9739-9744 (1999)			
	11.	Xie, M-H, et al (2000) J. Biol. Chem. Vol. 275(40):31335-31339			
	12.	Dumoutier, et al (2000) PNAS 97(18): 10144-10149			

S:\LACOMMON\PATENTS\AMEND\5358\CIP\PTO 1449 09-20-04.doc

Examiner	Date	
Signature	Considered	